Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

NCT03313661 is registered in ClinicalTrials.gov with Sherief Abd-Elsalam as lead sponsor.

NCT NCT03313661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03313661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients
Lead sponsor
Sherief Abd-Elsalam
Phase
Phase 3
Overall status
Unknown status
Start date
October 14, 2017
Completion date
December 31, 2020
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes